Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib versus physician's choice single-agent chemotherapy in germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
2014-003438-20Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib in ovarian cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Dec 2014; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2014-003438-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003438-20.